Gene expression profiling in acute allograft rejection: Challenging the immunologic constant of rejection hypothesis

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Spivey, Tara L ^a,b   Uccellini, Lorenzo ^a,c   Ascierto, Maria L ^a,d   Zoppoli, Gabriele ^d,e   De Giorgi, Valeria ^a   Delogu, Lucia G ^f   Engle, Alyson M ^a   Thomas, Jaime M ^a   Wang, Ena ^a   Marincola, Francesco M ^a   Bedognetti, Davide ^a,d,g  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e NATIONAL CANCER INSTITUTE   (United States)

^f UNIVERSITY OF SASSARI   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 10; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT REJECTION; ADAPTIVE IMMUNITY; B LYMPHOCYTE; COMPLEMENT SYSTEM; GENE; GENE EXPRESSION PROFILING; HUMAN; HYPOTHESIS; IMMUNOLOGIC CONSTANT OF REJECTION HYPOTHESIS; IMMUNOLOGY; INNATE IMMUNITY; INTERFERON STIMULATED GENE; MICROARRAY ANALYSIS; NATURAL KILLER CELL; REGULATORY T LYMPHOCYTE; REVIEW; ALLOTRANSPLANTATION; ARTICLE; BIOLOGICAL MODEL; DNA MICROARRAY; GENETICS; GRAFT REJECTION; SIGNAL TRANSDUCTION;

GENE EXPRESSION PROFILING; GRAFT REJECTION; HUMANS; MODELS, IMMUNOLOGICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 80053896382     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-174     Document Type: Review

References (198)

1. Panelli MC, Stashower ME, Slade HB, Smith K, Norwood C, Abati A, Fetsch P, Filie A, Walters SA, Astry C, et al. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biology 2007, 8.
2. Wang E, Miller LD, Ohnmacht GA, Mocellin S, Perez-Diaz A, Petersen D, Zhao YD, Simon R, Powell JI, Asaki E, et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Research 2002, 62:3581-3586.
3. Wang E, Worschech A, Marincola FM. The immunologic constant of rejection. Trends in Immunology 2008, 29:256-262.
4. Bedognetti D, Wang E, Sertoli MR, Marincola FM. Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Review of Vaccines 2010, 9:555-565.
5. Imanguli MM, Swaim WD, League SC, Gress RE, Pavletic SZ, Hakim FT. Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood 2009, 113:3620-3630.
6. He XS, Ji X, Hale MB, Cheung R, Ahmed A, Guo Y, Nolan GP, Pfeffer LM, Wright TL, Risch N, et al. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 2006, 44:352-359.
7. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, Schweigler LM, Theodore D, Zacks SL, Liang TJ, Fried MW. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007, 46:1548-1563.
8. Okamoto Y, Folco EJ, Minami M, Wara AK, Feinberg MW, Sukhova GK, Colvin RA, Kihara S, Funahashi T, Luster AD, Libby P. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res 2008, 102:218-225.
9. Costa C, Rufino R, Traves SL, Lapa ESJR, Barnes PJ, Donnelly LE. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest 2008, 133:26-33.
10. Kim MJ, Romero R, Kim CJ, Tarca AL, Chhauy S, LaJeunesse C, Lee DC, Draghici S, Gotsch F, Kusanovic JP, et al. Villitis of Unknown Etiology Is Associated with a Distinct Pattern of Chemokine Up-Regulation in the Feto-Maternal and Placental Compartments: Implications for Conjoint Maternal Allograft Rejection and Maternal Anti-Fetal Graft-versus-Host Disease. Journal of Immunology 2009, 182:3919-3927.
11. Patterson TA, Lobenhofer EK, Fulmer-Smentek SB, Collins PJ, Chu TM, Bao W, Fang H, Kawasaki ES, Hager J, Tikhonova IR, et al. Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. Nat Biotechnol 2006, 24:1140-1150.
12. Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 2006, 24:1151-1161.
13. Eikmans M, Roos-van Groningen MC, Sijpkens YWJ, Ehrchen J, Roth J, Baelde HJ, Bajema IM, de Fijter JW, de Heer E, Bruijn JA. Expression of surfactant protein-C, S100A8, S100A9, and B cell markers in renal allografts: Investigation of the prognostic value. Journal of the American Society of Nephrology 2005, 16:3771-3786.
14. Tannapfel A, Geissler F, Witzigmann H, Hauss J, Wittekind C. Analysis of liver allograft rejection related genes using cDNA-microarrays in liver allograft specimen. Transplantation Proceedings 2001, 33:3283-3284.
15. Sreekumar R, Rasmussen DL, Wiesner RH, Charlton MR. Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation. Liver Transplantation 2002, 8:814-821.
16. Inkinen K, Lahesmaa R, Brandt A, Katajamaa M, Halme L, Hockerstedt K, Lautenschlager I. DNA microarray-based gene expression profiles of cytomegalovirus infection and acute rejection in liver transplants. Transplantation Proceedings 2005, 37:1227-1229.
17. Gimino VJ, Lande JD, Berryman TR, King RA, Hertz MI. Gene expression profiling of bronchoalveolar lavage cells in acute lung rejection. American Journal of Respiratory and Critical Care Medicine 2003, 168:1237-1242.
18. Patil J, Lande JD, Li N, Berryman TR, King RA, Hertz MI. Bronchoalveolar lavage cell gene expression in acute lung rejection: Development of a diagnostic classifier. Transplantation 2008, 85:224-231.
19. Karason K, Jernas M, Hagg DA, Svensson PA. Evaluation of CXCL9 and CXCL10 as circulating biomarkers of human cardiac allograft rejection. BMC CardiovascDisord 2006, 6:29.
20. Bradley BA. Prognostic assays for rejection and tolerance in organ transplantation. Transplant Immunology 2005, 14:193-201.
21. Akalin E, Hendrix RC, Polavarapu RG, Pearson TC, Neylan JF, Larsen CP, Lakkis FG. Gene expression analysis in human renal allograft biopsy samples using high-density oligoarray technology. Transplantation 2001, 72:948-953.
22. Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek M, Salvatierra O. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. New England Journal of Medicine 2003, 349:125-138.
23. Flechner SM, Kurian SM, Head SR, Sharp SM, Whisenant TC, Zhang J, Chismar JD, Horvath S, Mondala T, Gilmartin T, et al. Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. American Journal of Transplantation 2004, 4:1475-1489.
24. Reeve J, Einecke G, Mengel M, Sis B, Kayser N, Kaplan B, Halloran PF. Diagnosing Rejection in Renal Transplants: A Comparison of Molecular- and Histopathology-Based Approaches. American Journal of Transplantation 2009, 9:1802-1810.
25. Morgun A, Shulzhenko N, Perez-Diez A, Diniz VZ, Sanson GF, Almeida DR, Matzinger P, Gerbase-DeLima M. Molecular profiling improves diagnoses of rejection and infection in transplanted organs. Circulation Research 2006, 98:E74-E83.
26. Saint-Mezard P, Berthier CC, Zhang H, Hertig A, Kaiser S, Schumacher M, Wieczorek G, Bigaud M, Kehren J, Rondeau E, et al. Analysis of independent microarray datasets of renal biopsies identifies a robust transcript signature of acute allograft rejection. Transplant International 2009, 22:293-302.
27. Chen R, Sigdel TK, Li L, Kambham N, Dudley JT, Hsieh SC, Klassen RB, Chen A, Caohuu T, Morgan AA, et al. Differentially expressed RNA from public microarray data identifies serum protein biomarkers for cross-organ transplant rejection and other conditions. PLoS Comput Biol 2010, 6.
28. Asaoka T, Kato T, Marubashi S, Dono K, Hama N, Takahashi H, Kobayashi S, Takeda Y, Takemasa I, Nagano H, et al. Differential transcriptome patterns for acute cellular rejection in recipients with recurrent hepatitis C after liver transplantation. Liver Transpl 2009, 15:1738-1749.
29. Rodder S, Scherer A, Korner M, Eisenberger U, Hertig A, Raulf F, Rondeau E, Marti HP. Meta-analyses qualify metzincins and related genes as acute rejection markers in renal transplant patients. Am J Transplant 2010, 10:286-297.
30. Lande JD, Patil J, Li N, Berryman TR, King RA, Hertz MI. Novel insights into lung transplant rejection by microarray analysis. Proc Am Thorac Soc 2007, 4:44-51.
31. Mueller TF, Einecke G, Reeve J, Sis B, Mengel M, Jhangri GS, Bunnag S, Cruz J, Wishart D, Meng C, et al. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. American Journal of Transplantation 2007, 7:2712-2722.
32. Bunnag S, Einecket G, Reeve J, Jhangri GS, Mueller TF, Sis B, Hidalgo LG, Mengel M, Kayser D, Kaplan B, Halloran PF. Molecular Correlates of Renal Function in Kidney Transplant Biopsies. Journal of the American Society of Nephrology 2009, 20:1149-1160.
33. Perco P, Kainz A, Wilflingseder J, Soleiman A, Mayer B, Oberbauer R. Histogenomics: Association of Gene Expression Patterns With Histological Parameters in Kidney Biopsies. Transplantation 2009, 87:290-295.
34. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF. Endothelial Gene Expression in Kidney Transplants with Alloantibody Indicates Antibody-Mediated Damage Despite Lack of C4d Staining. American Journal of Transplantation 2009, 9:2312-2323.
35. Sis B, Halloran PF. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Current Opinion in Organ Transplantation 2010, 15:42-48.
36. Mengel M, Reeve J, Bunnag S, Einecke G, Jhangri GS, Sis B, Famulski K, Guembes-Hidalgo L, Halloran PF. Scoring Total Inflammation Is Superior to the Current Banff Inflammation Score in Predicting Outcome and the Degree of Molecular Disturbance in Renal Allografts. American Journal of Transplantation 2009, 9:1859-1867.
37. Einecke G, Mengel M, Hidalgo L, Allanach K, Famulski KS, Halloran PF. The Early Course of Kidney Allograft Rejection: Defining the Time When Rejection Begins. American Journal of Transplantation 2009, 9:483-493.
38. Einecke G, Reeve J, Mengel M, Sis B, Bunnag S, Mueller TF, Halloran PF. Expression of B cell and immunoglobulin transcripts is a feature of inflammation in late allografts. American Journal of Transplantation 2008, 8:1434-1443.
39. Hidalgo LG, Sis B, Sellares J, Campbell PM, Mengel M, Einecke G, Chang J, Halloran PF. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 2010, 10:1812-1822.
40. Hidalgo LG, Einecke G, Allanach K, Mengel M, Sis B, Mueller TF, Halloran PF. The transcriptome of human cytotoxic T cells: Measuring the burden of CTL-Associated transcripts in human kidney transplants. American Journal of Transplantation 2008, 8:637-646.
41. Mengel M, Chang J, Kayser D, Gwinner W, Schwarz A, Einecke G, Broecker V, Famulski K, De Freitas DG, Guembes-Hidalgo L, et al. The Molecular Phenotype of 6-Week Protocol Biopsies from Human Renal Allografts: Reflections of Prior Injury but Not Future Course. Am J Transplant 2010,
42. Mengel M, Sis B, Kim D, Chang J, Famulski KS, Hidalgo LG, Einecke G, de Freitas DG, Tymchak W, Burton J, Halloran PF. The molecular phenotype of heart transplant biopsies: relationship to histopathological and clinical variables. Am J Transplant 2010, 10:2105-2115.
43. Famulski KS, Einecke G, Sis B, Mengel M, Hidalgo LG, Kaplan B, Halloran PF. Defining the canonical form of T-cell-mediated rejection in human kidney transplants. Am J Transplant 2010, 10:810-820.
44. Einecke G, Kayser D, Vanslambrouck JM, Sis B, Reeve J, Mengel M, Famulski KS, Bailey CG, Rasko JE, Halloran PF. Loss of solute carriers in T cell-mediated rejection in mouse and human kidneys: an active epithelial injury-repair response. Am J Transplant 2010, 10:2241-2251.
45. Einecke G, Reeve J, Sis B, Mengel M, Hidalgo L, Famulski KS, Matas A, Kasiske B, Kaplan B, Halloran PF. A molecular classifier for predicting future graft loss in late kidney transplant biopsies. J Clin Invest 2010, 120:1862-1872.
46. Mengel M, Allanach K, Einecke G, Sis B, Hidalgo L, Mueller T, Halloran PF. Comparing microarray versus RT-PCR assessment of renal allograft biopsies: Similar performance despite different dynamic ranges. American Journal of Transplantation 2008, 8:349-349.
47. Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Deng MC, Cappola TP, Kao A, Anderson AS, Cotts WG, Ewald GA, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med 2010, 362:1890-1900.
48. Schaub S, Nickerson P, Rush D, Mayr M, Hess C, Golian M, Stefura W, HayGlass K. Urinary CXCL9 and CXCL10 Levels Correlate with the Extent of Subclinical Tubulitis. American Journal of Transplantation 2009, 9:1347-1353.
49. Hauser IA, Spiegler S, Kiss E, Gauer S, Sichler O, Scheuermann EH, Ackermann H, Pfeilschifter JM, Geiger H, Grone HJ, Radeke HH. Prediction of acute renal allograft rejection by urinary monokine induced by IFN-gamma (MIG). Journal of the American Society of Nephrology 2005, 16:1849-1858.
50. Hu HZ, Aizenstein BD, Puchalski A, Burmania JA, Hamawy MM, Knechtle SJ. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. American Journal of Transplantation 2004, 4:432-437.
51. Tatapudi RR, Muthukumar T, Dadhania D, Ding R, Li BG, Sharma VK, Lozada-Pastorio E, Seetharamu N, Hartono C, Serur D, et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney International 2004, 65:2390-2397.
52. Hidalgo LG, Urmson J, Ramassar V, Halloran PF. IFN-gamma directly modulates lymphocyte cytotoxicity. Faseb Journal 2002, 16:A1086-A1086.
53. Hidalgo LG, Urmson J, Halloran PF. IFN-gamma decreases CTL generation by limiting IL-2 production: A feedback loop controlling effector cell production. American Journal of Transplantation 2005, 5:651-661.
54. Hidalgo LG, Halloran PF. Role of IFN-gamma in allograft rejection. Critical Reviews in Immunology 2002, 22:317-349.
55. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Advances in Immunology 2007, 96:41-101.
56. Kirk AD, Bollinger RR, Finn OJ. Rapid, Comprehensive Analysis of Human Cytokine Messenger-Rna and Its Application to the Study of Acute Renal-Allograft Rejection. Human Immunology 1995, 43:113-128.
57. Moudgil A, Bagga A, Toyoda M, Nicolaidou E, Jordan SC, Ross D. Expression of gamma-IFN mRNA in bronchoalveolar lavage fluid correlates with early acute allograft rejection in lung transplant recipients. Clinical Transplantation 1999, 13:201-207.
58. Nast CC, Zuo XJ, Prehn J, Danovitch GM, Wilkinson A, Jordan SC. Gamma-Interferon Gene-Expression in Human Renal-Allograft Fine-Needle Aspirates. Transplantation 1994, 57:498-502.
59. Lande JD, Gimino VJ, Hertz MI, King RA. Characterization of lung allograft rejection using microarray gene expression profiling. American Journal of Human Genetics 2002, 71:392-392.
60. Pos Z, Selleri S, Spivey TL, Wang JK, Liu H, Worschech A, Sabatino M, Monaco A, Leitman SF, Falus A, et al. Genomic scale analysis of racial impact on response to IFN-alpha. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:803-808.
61. de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, Silverman RH, Williams BRG. Functional classification of interferon-stimulated genes identified using microarrays. Journal of Leukocyte Biology 2001, 69:912-920.
62. Reeve J, Einecke G, Kaplan B, Halloran PF. A microarray-based classifier for diagnosing rejection in kidney transplants: The top diagnostic genes for rejection are interferon-gamma induced. American Journal of Transplantation 2008, 8:246-246.
63. Ramassar V, Urmson J, Hobart M, Goes N, Halloran PF. Class II transactivator (CIITA) mediates the in vivo induction of class II in mouse tissues. Faseb Journal 1996, 10:2262-2262.
64. Goes N, Hobart M, Ramassar V, Halloran PF. Role of IFN-gamma and IRF-1 in injury-induced and basal MHC class I and II expression. Faseb Journal 1996, 10:2184-2184.
65. Zhu JF, Paul WE. CD4 T cells: fates, functions, and faults. Blood 2008, 112:1557-1569.
66. Ramsey SA, Klemm SL, Zak DE, Kennedy KA, Thorsson V, Li B, Gilchrist M, Gold ES, Johnson CD, Litvak V, et al. Uncovering a macrophage transcriptional program by integrating evidence from motif scanning and expression dynamics. Plos Computational Biology 2008, 4.
67. Yeruva S, Ramadori G, Raddatz D. NF-kappa B-dependent synergistic regulation of CXCL10 gene expression by IL-1 beta and IFN-gamma in human intestinal epithelial cell lines. International Journal of Colorectal Disease 2008, 23:305-317.
68. Liu JG, Guan XQ, Ma XJ. Interferon regulatory factor 1 is an essential and direct transcriptional activator for interferon gamma-induced RANTES/CC15 expression in macrophages. Journal of Biological Chemistry 2005, 280:24347-24355.
69. Zhao DXM, Hu YY, Miller GG, Luster AD, Mitchell RN, Libby P. Differential expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: Association with cardiac allograft vasculopathy and acute rejection. Journal of Immunology 2002, 169:1556-1560.
70. Fahmy NM, Yamani MH, Starling RC, Ratliff NB, Young JB, McCarthy PM, Feng JY, Novick AC, Fairchild RL. Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation 2003, 75:72-78.
71. Belperio JA, Keane MP, Burdick MD, Lynch JP, Zisman DA, Xue YY, Li KW, Ardehali A, Ross DJ, Strieter RM. Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection. Journal of Immunology 2003, 171:4844-4852.
72. Melter M, Exeni A, Reinders MEJ, Fang JC, McMahon G, Ganz P, Hancock WW, Briscoe DM. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 2001, 104:2558-2564.
73. Fischereder M, Luckow B, Hocher B, Wuthrich RP, Rothenpieler U, Schneeberger H, Panzer U, Stahl RAK, Hauser IA, Budde K, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001, 357:1758-1761.
74. Heidenhain C, Pulhl G, Moench C, Lautem A, Neuhaus P. Chemokine receptor 5 Delta 32 mutation reduces the risk of acute rejection in liver transplantation. Annals of Transplantation 2009, 14:36-44.
75. Hancock WW, Lu B, Gao W, Csizmadia V, Faia K, King JA, Smiley ST, Ling M, Gerard NP, Gerard C. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. Journal of Experimental Medicine 2000, 192:1515-1519.
76. Hancock WW, Gao W, Csizmadia V, Faia KL, Shemmeri N, Luster AD. Donor-derived IP-10 initiates development of acute allograft rejection. Journal of Experimental Medicine 2001, 193:975-980.
77. Hancock WW, Wang LQ, Ye QR, Han RX, Lee I. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Current Opinion in Immunology 2003, 15:479-486.
78. Gao W, Faia KL, Csizmadia V, Smiley ST, Soler D, King JA, Danoff TM, Hancock WW. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001, 72:1199-1205.
79. Gao P, Zhou XY, Yashiro-Ohtani Y, Yang YF, Sugimoto N, Ono S, Nakanishi T, Obika S, Imanishi T, Egawa T, et al. The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. Journal of Leukocyte Biology 2003, 73:273-280.
80. Halloran PF, Fairchild RL. The puzzling role of CXCR3 and its ligands in organ allograft rejection. American Journal of Transplantation 2008, 8:1578-1579.
81. Haskova Z, Izawa A, Contreras AG, Flynn E, Boulday G, Briscoe DM. Organ-specific differences in the function of MCP-1 and CXCR3 during cardiac and skin allograft rejection. Transplantation 2007, 83:1595-1601.
82. Kwun J, Hazinedaroglu SM, Schadde E, Kayaoglu HA, Fechner J, Hu HZ, Roenneburg D, Torrealba J, Shiao L, Hong X, et al. Unaltered graft survival and intragraft lymphocytes infiltration in the cardiac allograft of Cxcr3(-/-) mouse recipients. American Journal of Transplantation 2008, 8:1593-1603.
83. Zerwes HG, Li J, Kovarik J, Streiff M, Hofmann M, Roth L, Luyten M, Pally C, Loewe RP, Wieczorek G, et al. The chemokine receptor Cxcr3 is not essential for acute cardiac allograft rejection in mice and rats. American Journal of Transplantation 2008, 8:1604-1613.
84. Morris MA, Ley K. Trafficking of natural killer cells. Curr Mol Med 2004, 4:431-438.
85. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacological Reviews 2000, 52:145-176.
86. Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends in Immunology 2004, 25:75-84.
87. Deola S, Panelli MC, Maric D, Selleri S, Dmitrieva NI, Voss CY, Klein H, Stroncek D, Wang E, Marincola FM. Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation through CD27/CD70 interactions. Journal of Immunology 2008, 180:1362-1372.
88. Hoffmann U, Sergerer S, Rummele P, Kruger B, Pietrzyk M, Hofstadter F, Banas B, Kramer BK. Expression of the chemokine receptor CXCR3 in human renal allografts-a prospective study. Nephrology Dialysis Transplantation 2006, 21:1373-1381.
89. Xanthou G, Duchesnes CE, Williams TJ, Pease JE. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11. Eur J Immunol 2003, 33:2241-2250.
90. Halloran PF. T cell-mediated rejection of kidney transplants: a personal viewpoint. Am J Transplant 2010, 10:1126-1134.
91. Qin SX, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch AE, Moser B, Mackay CR. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. Journal of Clinical Investigation 1998, 101:746-754.
92. Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 2000, 95:627-632.
93. Drayton DL, Liao S, Mounzer RH, Ruddle NH. Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol 2006, 7:344-353.
94. Krensky AM, Clayberger C. Biology and clinical relevance of granulysin. Tissue Antigens 2009, 73:193-198.
95. Obara H, Nagasaki K, Hsieh CL, Ogura Y, Esquivel CO, Martinez OM, Krams SM. IFN-gamma, produced by NK cells that infiltrate liver allografts early after transplantation, links the innate and adaptive immune responses. Am J Transplant 2005, 5:2094-2103.
96. Kondo T, Morita K, Watarai Y, Auerbach MB, Taub DD, Novick AC, Toma H, Fairchild RL. Early increased chemokine expression and production in murine allogeneic skin grafts is mediated by natural killer cells. Transplantation 2000, 69:969-977.
97. Larosa DF, Rahman AH, Turka LA. The innate immune system in allograft rejection and tolerance. Journal of Immunology 2007, 178:7503-7509.
98. Kitchens WH, Uehara S, Chase CM, Colvin RB, Russell PS, Madsen JC. The changing role of natural killer cells in solid organ rejection and tolerance. Transplantation 2006, 81:811-817.
99. Bingaman AW, Ha J, Waitze SY, Durham MM, Cho HR, Tucker-Burden C, Hendrix R, Cowan SR, Pearson TC, Larsen CP. Vigorous allograft rejection in the absence of danger. Journal of Immunology 2000, 164:3065-3071.
100. Worschech A, Chen NH, Yu YA, Zhang Q, Pos Z, Weibel S, Raab V, Sabatino M, Monaco A, Liu H, et al. Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. Bmc Genomics 2009, 10.
101. Andersen CB, Ladefoged SD, Larsen S. Acute Kidney Graft-Rejection - A Morphological and Immunohistological Study on Zero-Hour and Follow-Up Biopsies with Special Emphasis on Cellular Infiltrates and Adhesion Molecules. Apmis 1994, 102:23-37.
102. Meehan SM, McCluskey RT, Pascual M, Preffer FI, Anderson P, Schlossman SF, Colvin RB. Cytotoxicity and apoptosis in human renal allografts: Identification, distribution, and quantitation of cells with a cytotoxic granule protein GMP-17 (TIA-1) and cells with fragmented nuclear DNA. Laboratory Investigation 1997, 76:639-649.
103. Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, Chapman S, Craciun L, Sergeant R, Brouard S, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010, 120:1848-1861.
104. Cassese G, Lindenau S, de Boer B, Arce S, Hauser A, Riemekasten G, Berek C, Hiepe F, Krenn V, Radbruch A, Manz RA. Inflamed kidneys of NZB/W mice are a major site for the homeostasis of plasma cells. European Journal of Immunology 2001, 31:2726-2732.
105. Magalhaes R, Stiehl P, Morawietz L, Berek C, Krenn V. Morphological and molecular pathology of the B cell response in synovitis of rheumatoid arthritis. Virchows Archiv 2002, 441:415-427.
106. Platt JL, Lebien TW, Michael AF. Interstitial Mononuclear Cell-Populations in Renal Graft-Rejection - Identification by Monoclonal-Antibodies in Tissue-Sections. Journal of Experimental Medicine 1982, 155:17-30.
107. Zarkhin V, Sarwal MM. Microarrays: Monitoring for Transplant Tolerance and Mechanistic Insights. Clinics in Laboratory Medicine 2008, 28:385-+.
108. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, et al. Antibody-mediated rejection criteria - an addition to the Banff '97 Classification of Renal Allograft Rejection. American Journal of Transplantation 2003, 3:708-714.
109. Alausa M, Almagro U, Siddiqi N, Zuiderweg R, Medipalli R, Hariharan S. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab. Clinical Transplantation 2005, 19:137-140.
110. Bagnasco SM, Tsai W, Rahman MH, Kraus ES, Barisoni L, Vega R, Racusen LC, Haas M, Mohammed BS, Zachary AA, Montgomery RA. CD20-positive infiltrates in renal allograft biopsies with acute cellular rejection are not associated with worse graft survival. American Journal of Transplantation 2007, 7:1968-1973.
111. Doria C, di Francesco F, Ramirez CB, Frank A, Iaria M, Francos G, Marino IR, Farber JL. The presence of B-cell nodules does not necessarily portend a less favorable outcome to therapy in patients with acute cellular rejection of a renal allograft. Transplantation Proceedings 2006, 38:3441-3444.
112. Hippen BE, DeMattos A, Cook WJ, Kew CE, Gaston RS. Association of CD20+infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. American Journal of Transplantation 2005, 5:2248-2252.
113. Kayler LK, Lakkis FG, Morgan C, Basu A, Blisard D, Tan HP, Shapiro R, Randhawa PS. Acute cellular rejection with CD20-Positive lymphoid clusters in kidney transplant patients following lymphocyte depletion. American Journal of Transplantation 2007, 7:357-357.
114. Krukemeyer MG, Moeller J, Morawietz L, Rudolph B, Neumann U, Theruvath T, Neuhaus P, Krenn V. Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. Transplantation 2004, 78:65-70.
115. Tsai EW, Rianthavorn P, Gjertson DW, Wallace WD, Reed EF, Ettenger RB. CD20+lymphocytes in renal allografts are associated with poor graft survival in pediatric patients. Transplantation 2006, 82:1769-1773.
116. Mengel M, Bogers J, Bosmans JL, Seron D, Moreso F, Carrera M, Gwinner W, Schwarz A, De Broe M, Kreipe H, Haller H. Incidence of C4d stain in protocol biopsies from renal allografts: Results from a multicenter trial. American Journal of Transplantation 2005, 5:1050-1056.
117. Martins HL, Silva C, Martini D, Noronha IL. Detection of B lymphocytes (CD20(+)) in renal allograft biopsy specimens. Transplantation Proceedings 2007, 39:432-434.
118. Zarkhin V, Kambham N, Li L, Kwok S, Hsieh SC, Salvatierra O, Sarwal MM. Characterization of intra-graft B cells during renal allograft rejection. Kidney International 2008, 74:664-673.
119. Noorchashm H, Reed AJ, Rostami SY, Mozaffari R, Zekavat G, Koeberlein B, Caton AJ, Naji A. B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. Journal of Immunology 2006, 177:7715-7722.
120. Schultz KR, Klarnet JP, Gieni RS, Hayglass KT, Greenberg PD. The Role of B-Cells for Invivo T-Cell Responses to A Friend Virus-Induced Leukemia. Science 1990, 249:921-923.
121. Yang X, Brunham RC. Gene knockout B cell-deficient mice demonstrate that B cells play an important role in the initiation of T cell responses to Chlamydia trachomatis (mouse pneumonitis) lung infection. Journal of Immunology 1998, 161:1439-1446.
122. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. Journal of Neuroimmunology 2006, 180:63-70.
123. Ascierto M, Kmieciak M, Idowu M, Manjili R, Zhao Y, Nikizad H, Grimes M, Dumur C, Wang E, Wang X, et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Resarch and Treatment 2011,
124. Zarkhin V, Chalasani G, Sarwal MM. The yin and yang of B cells in graft rejection and tolerance. Transplant Rev (Orlando) 2010, 24:67-78.
125. Tyden G, Genberg H, Tollemar J, Ekberg H, Persson NH, Tufveson G, Wadstrom J, Gabel M, Mjornstedt L. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009, 87:1325-1329.
126. Clatworthy MR, Watson CJ, Plotnek G, Bardsley V, Chaudhry AN, Bradley JA, Smith KG. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009, 360:2683-2685.
127. Bedognetti D, Zoppoli G, Massucco C, Zanardi E, Zupo S, Bruzzone A, Sertoli MR, Balleari E, Racchi O, Messina M, et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. J Immunol 2011, 186:6044-55.
128. Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, Burlingham WJ, Marks WH, Sanz I, Lechler RI, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010, 120:1836-1847.
129. Louis S, Braudeau C, Giral M, Dupont A, Moizant F, Robillard N, Moreau A, Soulillou JP, Brouard S. Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006, 81:398-407.
130. Pallier A, Hillion S, Danger R, Giral M, Racape M, Degauque N, Dugast E, Ashton-Chess J, Pettre S, Lozano JJ, et al. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 2010, 78:503-513.
131. Sharma R, Jarjour WN, Zheng L, Gaskin F, Fu SM, Ju ST. Large functional repertoire of regulatory T-cell suppressible autoimmune T cells in scurfy mice. J Autoimmun 2007, 29:10-19.
132. Wildin RS, Freitas A. IPEX and FOXP3: clinical and research perspectives. J Autoimmun 2005, (25 Suppl):56-62.
133. Lee WS, Park S, Lee WY, Yun SH, Chun HK. Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer. Cancer 2010, 116:5188-5199.
134. Correale P, Rotundo MS, Del Vecchio MT, Remondo C, Migali C, Ginanneschi C, Tsang KY, Licchetta A, Mannucci S, Loiacono L, et al. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother 2010, 33:435-441.
135. Muthukumar T, Dadhania D, Ding R, Snopkowski C, Naqvi R, Lee JB, Hartono C, Li B, Sharma VK, Seshan SV, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005, 353:2342-2351.
136. Bunnag S, Allanach K, Jhangri GS, Sis B, Einecke G, Mengel M, Mueller TF, Halloran PF. FOXP3 expression in human kidney transplant biopsies is associated with rejection and time post transplant but not with favorable outcomes. American Journal of Transplantation 2008, 8:1423-1433.
137. Matzinger P. The danger model: A renewed sense of self. Science 2002, 296:301-305.
138. Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H. HSP70 as endogenous stimulus of the toll/interleukin-1 receptor signal pathway. Journal of Biological Chemistry 2002, 277:15107-15112.
139. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nature Reviews Immunology 2005, 5:375-386.
140. Reich NC, Liu L. Tracking STAT nuclear traffic. Nature Reviews Immunology 2006, 6:602-612.
141. Muller-Ladner U, Alten R, Heiligenhaus A, Kekow J, Koletzko S, Mrowietz U, Ochsenkuhn T, Radke M, Reich K, Rudwaleit M, Schreiber S. "TRECID", TNF alpha related chronic inflammatory diseases - A new multiple diseases bridging concept. Deutsche Medizinische Wochenschrift 2009, 134:2132-2136.
142. Connolly MK, Bedrosian AS, Clair JMS, Mitchell AP, Ibrahim J, Stroud A, Pachter HL, Bar-Sagi D, Frey AB, Miller G. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. Journal of Clinical Investigation 2009, 119:3213-3225.
143. Le Moine A, Goldman M, Abramowicz D. Multiple pathways to allograft rejection. Transplantation 2002, 73:1373-1381.
144. Bonizzi G, Karin M. The two NF-kappa B activation pathways and their role in innate and adaptive immunity. Trends in Immunology 2004, 25:280-288.
145. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
146. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nature Immunology 2004, 5:987-995.
147. Brent L. The 50th anniversary of the discovery of immunologic tolerance. New England Journal of Medicine 2003, 349:1381-1383.
148. Brouard S, Mansfield E, Braud C, Li L, Giral M, Hsieh SC, Baeten D, Zhang M, Ashton-Chess J, Braudeau C, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:15448-15453.
149. Lin T, Zhou WD, Sacks SH. The role of complement and Toll-like receptors in organ transplantation. Transplant International 2007, 20:481-489.
150. Sacks S, Lee Q, Wong W, Zhou W. The role of complement in regulating the alloresponse. Current Opinion in Organ Transplantation 2009, 14:10-15.
151. Sacks SH, Chowdhury P, Zhou WD. Role of the complement system in rejection. Current Opinion in Immunology 2003, 15:487-492.
152. Lee JI, Burckart GJ. Nuclear factor kappa B: Important transcription factor and therapeutic target. Journal of Clinical Pharmacology 1998, 38:981-993.
153. Schreiber J, Jenner RG, Murray HL, Gerber GK, Gifford DK, Young RA. Coordinated binding of NF-kappa B family members in the response of human cells to lipopolysaccharide. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:5899-5904.
154. Peng Q, Li K, Patel H, Sacks SH, Zhou WD. Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype. Journal of Immunology 2006, 176:3330-3341.
155. Kawamoto S, Yalcindag A, Laouini D, Brodeur S, Bryce P, Lu B, Humbles AA, Oettgen H, Gerard C, Geha RS. The anaphylatoxin C3a downregulates the Th2 response to epicutaneously introduced antigen. Journal of Clinical Investigation 2004, 114:399-407.
156. Carroll MC. The complement system in B cell regulation. Molecular Immunology 2004, 41:141-146.
157. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nature Medicine 2002, 8:582-587.
158. Li K, Patel H, Farrar CA, Hargreaves REG, Sacks SH, Zhou WD. Complement activation regulates the capacity of proximal tubular epithelial cell to stimulate alloreactive T cell response. Journal of the American Society of Nephrology 2004, 15:2414-2422.
159. Cordoba SP, Wang CM, Williams R, Li J, Smit L, Sharland A, Allen R, McCaughan G, Bishop A. Gene array analysis of a rat model of liver transplant tolerance identifies increased complement C3 and the STAT-1/IRF-1 pathway during tolerance induction. Liver Transplantation 2006, 12:636-643.
160. Fujino M, Kitazawa Y, Kawasaki M, Funeshima N, Kimura H, Nakajima T, Saito H, Li XK. Differences in lymphocyte gene expression between tolerant and syngeneic liver grafted rats. Liver Transplantation 2004, 10:379-391.
161. Pan TL, Wang PW, Huang CC, Goto S, Chen CL. Expression, by functional proteomics, of spontaneous tolerance in rat orthotopic liver transplantation. Immunology 2004, 113:57-64.
162. Naesens M, Li L, Ying LH, Sansanwal P, Sigdel TK, Hsieh SC, Kambham N, Lerut E, Salvatierra O, Butte AJ, Sarwal MM. Expression of Complement Components Differs Between Kidney Allografts from Living and Deceased Donors. Journal of the American Society of Nephrology 2009, 20:1839-1851.
163. Moore KW, Malefyt RD, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annual Review of Immunology 2001, 19:683-765.
164. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. The dual role of IL-10. Trends in Immunology 2003, 24:36-43.
165. Mocellin S, Panelli M, Wang E, Rossi CR, Pilati P, Nitti D, Lise M, Marincola FM. IL-10 stimulatory effects on human NK cells explored by gene profile analysis. Genes and Immunity 2004, 5:621-630.
166. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. Journal of Leukocyte Biology 2005, 78:1043-1051.
167. Tao M, Li BR, Nayini J, Sivaraman S, Song SW, Larson A, Toofanfard M, Chen H, Venugopal P, Preisler HD. In vivo effects of IL-4, IL-10, and amifostine on cytokine production in patients with acute myelogenous leukemia. Leukemia & Lymphoma 2001, 41:161-168.
168. Lauw FN, Pajkrt D, Hack CE, Kurimoto M, van Deventer SJH, van der Poll T. Proinflammatory effects of IL-10 during human endotoxemia. Journal of Immunology 2000, 165:2783-2789.
169. Del Vecchio M, Mortarini R, Canova S, Di Guardo L, Pimpinelli N, Sertoli MR, Bedognetti D, Queirolo P, Morosini P, Perrone T, et al. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. Clin Cancer Res 2010, 16:5862-5872.
170. Qian SG, Li W, Li YP, Fu FM, Lu LN, Fung JJ, Thomson AW. Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection in mice. Transplantation 1996, 62:1709-1714.
171. Li W, Lu L, Li Y, Fu F, Fung JJ, Thomson AW, Qian S. High-dose cellular IL-10 exacerbates rejection and reverses effects of cyclosporine and tacrolimus in mouse cardiac transplantation. Transplantation Proceedings 1997, 29:1081-1082.
172. Li W, Fu F, Lu L, Narula SK, Fung JJ, Thomson AW, Qian S. Systemic administration of anti-interleukin-10 antibody prolongs organ allograft survival in normal and presensitized recipients. Transplantation 1998, 66:1587-1596.
173. Karczewski J, Karczewski M, Wiktorowicz K, Glyda M. Cytometric Analysis of Th1/Th2 Cytokines in the Urine of Patients Prior to the Kideny Transplantation. Transplant International 2009, 22:145-145.
174. Grinyo J, Vanrenterghem Y, Nashan B, Vincenti F, Ekberg H, Lindpaintner K, Rashford M, Nasmyth-Miller C, Voulgari A, Spleiss O, et al. Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transplant International 2008, 21:879-891.
175. Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nature Reviews Immunology 2006, 6:644-658.
176. Vila-del Sol V, Punzon C, Fresno M. IFN-gamma-induced TNF-alpha expression is regulated by interferon regulatory factors 1 and 8 in mouse macrophages. Journal of Immunology 2008, 181:4461-4470.
177. Penninger JM, Sirard C, Mittrucker HW, Chidgey A, Kozieradzki I, Nghiem M, Hakem A, Kimura T, Timms E, Boyd R, et al. The interferon regulatory transcription factor IRF-1 controls positive and negative selection of CD8(+) thymocytes. Immunity 1997, 7:243-254.
178. Taki S, Sato T, Ogasawara K, Fukuda T, Sato M, Hida S, Suzuki G, Mitsuyama M, Shin EH, Kojima S, et al. Multistage regulation of Th1-type immune responses by the transcription factor IRF-1. Immunity 1997, 6:673-679.
179. Ogasawara K, Hida S, Azimi N, Tagaya Y, Sato T, Yokochi-Fukuda T, Waldmann TA, Taniguchi T, Taki S. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells (vol 391, pg 700, 1998). Nature 1998, 392:843-843.
180. Hama N, Yanagisawa Y, Dono K, Kobayashi S, Marubashi S, Nagano H, Umeshita K, Watanabe S, Uchiyama Y, Monden M. Gene Expression Profiling of Acute Cellular Rejection in Rat Liver Transplantation Using DNA Microarrays. Liver Transplantation 2009, 15:509-521.
181. Stegall M, Park W, Kim D, Kremers W. Gene expression during acute allograft rejection: Novel statistical analysis of microarray data. American Journal of Transplantation 2002, 2:913-925.
182. Erickson LM, Pan F, Ebbs A, Kobayashi M, Jiang HS. Microarray-based gene expression profiles of allograft rejection and immunosuppression in the rat heart transplantation model. Transplantation 2003, 76:582-588.
183. Kroger A, Koster M, Schroeder K, Hauser H, Mueller PP. Activities of IRF-1. Journal of Interferon and Cytokine Research 2002, 22:5-14.
184. Jin P, Wang E, Provenzano M, Stroncekl D, Marincoial FM. Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy. Critical Reviews in Immunology 2007, 27:437-448.
185. Matsuyama T, Kimura T, Kitagawa M, Pfeffer K, Kawakami T, Watanabe N, Kundig TM, Amakawa R, Kishihara K, Wakeham A, et al. Targeted Disruption of Irf-1 Or Irf-2 Results in Abnormal Type-I Ifn Gene Induction and Aberrant Lymphocyte Development. Cell 1993, 75:83-97.
186. Erickson L, Crews G, Pan F, Fisniku O, Jang MS, Wynn C, Kobayashi M, Jiang HS. Unique gene expression profiles of heart allograft rejection in the interferon regulatory factor-1-deficient mouse. Transplant Immunology 2004, 13:169-175.
187. Mansfield ES, Sarwal MM. Arraying the orchestration of allograft pathology. American Journal of Transplantation 2004, 4:853-862.
188. Bonadies N, Neururer C, Steege A, Vallabhapurapu S, Pabst T, Mueller BU. PU.1 is regulated by NF-kappaB through a novel binding site in a 17 kb upstream enhancer element. Oncogene 2010, 29:1062-1072.
189. Finn PW, Stone JR, Boothby MR, Perkins DL. Inhibition of NF-kappa B-dependent T cell activation abrogates acute allograft rejection. Journal of Immunology 2001, 167:5994-6001.
190. Basil CF, Zhao YD, Zavaglia K, Jin P, Panelli MC, Voiculescu S, Mandruzzato S, Lee HM, Seliger B, Freedman RS, et al. Common cancer biomarkers. Cancer Research 2006, 66:2953-2961.
191. Tiao MM, Lu L, Tao R, Wang L, Fung JJ, Qian SG. Prolongation of cardiac allograft survival by systemic administration of immature recipient dendritic cells deficient in NF-kappa B activity. Annals of Surgery 2005, 241:497-505.
192. Ohmori K, Takeda S, Miyoshi S, Minami M, Nakane S, Ohta M, Sawa Y, Matsuda H. Attenuation of lung injury in allograft rejection using NF-kappa B decoy transfection - novel strategy for use in lung transplantation. European Journal of Cardio-Thoracic Surgery 2005, 27:23-27.
193. Zhou P, Hwang KW, Palucki DA, Guo Z, Boothby M, Newell KA, Alegre ML. Impaired NF-kappa B activation in T cells permits tolerance to primary heart allografts and to secondary donor skin grafts. American Journal of Transplantation 2003, 3:139-147.
194. Marincola FM, Wang E. Immunologic signatures of rejection. 2010, New York, NY: Springer.
195. Pos Z, Galon J. Predictors of favorable outcome in cancer. Immunologic signatures of rejection 2010, 199-210. New York: Springer, Marincola FM, Wang E.
196. Bedognetti D. Signatures Associated with Acute Rejection: Allograft Rejection. In: Immunologic signatures of rejection. 2010, 305-345. New York: Springer, Marincola FM, Wang E.
197. Ascierto ML, De Giorgi V, Liu Q, Bedognetti D, Spivey T, Murtas D, Uccellini L, Ayotte BD, Stroncek DF, Chouchane L, et al. An immunologic portrait of cancer. J Transl Med 2011,
198. Castiello L, Sabatino M, Jin P, Clayberger C, Marincola FM, Krensky AM, Stroncek DF. Monocyte-derived DC maturation strategies and related pathways: a transcriptional view. Cancer Immunol Immunother 2011, 60:457-466.